Navigating Corporate Practice of Medicine Restrictions for DTC Telehealth Weight Loss Brands

The landscape for direct-to-consumer (DTC) telehealth weight loss brands is rapidly evolving, driven by technological advancements and increasing patient demand for convenient access to care. However, these innovative models often collide with long-standing state-specific regulatory frameworks, most notably the Corporate Practice of Medicine (CPOM) doctrine. For any telehealth entity, particularly those involved in prescribing medications such as GLP-1 agonists, understanding and meticulously adhering to CPOM laws is critical for sustainable and compliant operation.

Understanding the Corporate Practice of Medicine (CPOM) Doctrine

The Corporate Practice of Medicine doctrine is a legal principle that generally prohibits corporations, or other non-physician entities, from employing physicians or otherwise interfering with the independent professional judgment of licensed medical practitioners. The primary intent of CPOM laws is to safeguard the integrity of the physician-patient relationship, preventing commercial interests from influencing medical decisions and ensuring that healthcare remains focused on patient welfare rather than profit.

While CPOM statutes vary significantly by state, common prohibitions include:

• Employment of Physicians by Non-Physician Entities: Corporations typically cannot directly employ physicians to provide medical services.
• Fee-Splitting: Prohibiting the sharing of professional fees with non-licensed individuals or entities.
• Control Over Medical Decisions: Preventing non-physician entities from dictating or influencing a physician's clinical judgment, treatment protocols, or prescribing practices.
• Ownership of Medical Practices: In many states, medical practices must be owned and controlled by licensed physicians.

These doctrines are often enshrined in state statutes, medical board regulations, and attorney general opinions. For example, states like California (e.g., Business and Professions Code § 2400) and Texas (e.g., Occupations Code § 155.001) are known for their strict CPOM enforcement, while others like New York (e.g., Education Law § 6512) and Illinois (e.g., 225 ILCS 60/22) also maintain robust prohibitions. Conversely, some states have more relaxed CPOM interpretations or explicit exceptions.

Impact on DTC Telehealth Weight Loss Brands

DTC telehealth weight loss brands often operate by connecting patients with licensed providers through a technology platform, facilitating consultations, and, where appropriate, prescribing medications. The corporate entity typically handles marketing, technology, administrative support, and billing. This structure inherently raises CPOM concerns, as the corporate entity is not physician-owned and could be perceived as practicing medicine or controlling medical services.

Key Compliance Challenges:

1. Physician Employment vs. Independent Contractor Status: Many CPOM states prohibit the direct employment of physicians by non-professional corporations. Telehealth platforms must structure their relationships with providers as independent contractors or through a Management Service Organization (MSO) model. In an MSO model, the corporate entity provides non-clinical administrative and business services to an independently owned and operated professional medical corporation (PC) or professional limited liability company (PLLC), which directly employs or contracts with the physicians. The PC/PLLC is typically owned by one or more licensed physicians.

2. Fee-Splitting Prohibitions: CPOM states strictly regulate how professional fees can be shared. A common violation occurs when a corporate entity charges a percentage of the professional fees generated by the physician or bases its service fees on the volume or value of medical services. MSO agreements must ensure that the administrative fees charged by the corporate entity are for legitimate, fair market value services (e.g., technology, marketing, billing, office space) and are not contingent on the amount of medical services rendered or prescriptions written.

3. Clinical Autonomy: The corporate entity must not exert any control over the physician's medical judgment. This means the platform cannot dictate treatment protocols, influence prescribing decisions (e.g., favoring certain medications or pharmacies), or interfere with the physician's assessment of medical necessity. All clinical decisions, including the decision to prescribe weight loss medications, must remain solely with the licensed practitioner.

4. Ownership and Control of Patient Records: While the telehealth platform may host patient data, the medical record is ultimately the property of the patient and the treating physician/practice. The corporate entity's access and use of this data must be limited to facilitating administrative services and must comply with HIPAA and other privacy regulations.

Specific Considerations for Weight Loss Services and Prescribing

Weight loss services, particularly those involving prescription medications like GLP-1 agonists (e.g., Ozempic, Wegovy, Mounjaro), attract heightened regulatory scrutiny. State medical boards and federal agencies are increasingly focused on appropriate prescribing practices, patient safety, and the prevention of fraud and abuse.

• Medical Necessity and Appropriate Prescribing: Physicians must conduct thorough evaluations, including medical history, physical examinations (which may be conducted via telehealth if clinically appropriate and permitted by state law), and diagnostic tests to determine medical necessity for weight loss medications. Prescribing solely based on patient request or without a comprehensive assessment can lead to medical board discipline.
• Off-Label Prescribing: While physicians can prescribe medications off-label, it must be based on sound medical evidence and clinical judgment. Telehealth platforms must not encourage or facilitate off-label prescribing for commercial gain.
• Compounding Pharmacies: The use of compounded GLP-1s has drawn significant attention from the FDA and state pharmacy boards. Telehealth brands must ensure that any engagement with compounding pharmacies is compliant with federal and state regulations, including those related to drug quality, safety, and appropriate prescribing practices. The FDA has issued warnings regarding unapproved compounded versions of semaglutide and tirzepatide.

Mitigating CPOM Risk: The MSO Model

The Management Service Organization (MSO) model is the most common legal structure used by DTC telehealth companies to comply with CPOM laws. In this model:

1. Professional Entity: A professional medical corporation (PC) or professional limited liability company (PLLC) is formed, owned by one or more licensed physicians. This entity directly employs or contracts with the treating physicians and provides all medical services.
2. MSO Entity: A separate corporate entity (the MSO) provides non-clinical administrative, technical, and business support services to the PC/PLLC. These services may include technology platform, marketing, billing, scheduling, human resources, and facilities management.
3. MSO Agreement: A comprehensive MSO agreement defines the relationship, ensuring that the MSO's services are purely administrative, do not involve clinical decision-making, and are compensated at fair market value. The agreement explicitly states that the PC/PLLC retains full control over all medical aspects of the practice.

Crucially, the MSO agreement must be carefully drafted to avoid any appearance of the MSO controlling the medical practice or engaging in prohibited fee-splitting. The compensation structure for the MSO must be fixed or based on a legitimate cost-plus model, not tied to the volume or value of medical services provided by the PC/PLLC.

Conclusion

DTC telehealth weight loss brands operating in states with strict CPOM doctrines face a complex regulatory environment. Compliance requires a deep understanding of state-specific laws, careful legal structuring (often through an MSO model), and a commitment to maintaining physician independence and patient-centric care. Proactive legal counsel and robust internal compliance programs are indispensable to navigate these challenges, mitigate regulatory risk, and ensure the long-term viability of innovative telehealth models. Failure to comply can result in severe penalties, including license revocation, civil fines, and criminal charges.

---

References

• California Business and Professions Code: https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?sectionNum=2400.&lawCode=BPC
• Texas Occupations Code: https://statutes.capitol.texas.gov/Docs/OC/htm/OC.155.htm
• New York Education Law: https://www.nysenate.gov/legislation/laws/EDN/6512
• Illinois Medical Practice Act of 1987: https://www.ilga.gov/legislation/ilcs/ilcs3.asp?ActID=1327&ChapterID=24
• FDA Statements on Compounded Semaglutide: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-used-diabetes-and-weight-loss-supply-issues-and-use-compounded-drugs